Key Features
- Actionable results with 98% accuracy
- Quantifies the excess or deficit vs patient-specific ideal
- Non-invasive, single-venipuncture technique
Latest News
DDN-News features story on Daxor’s BVA-100
Device Daily News story “It’s all in the volume measurement” by Mel J. Yeates published 10/15/18: https://www.ddn-news.com/index.php?newsarticle=12809
Daxor Corporation to Present at The MicroCap Conference on October 2, 2018
NEW YORK – September 25, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, today announced that Michael Feldschuh, chief executive officer of Daxor, will be a featured presenter at The MicroCap Conference on Tuesday, October 2, 2018 at 4:30 PM ET. The conference is […]
New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate Measurements
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo Clinic studies showing that direct blood volume analysis provides doctors with important information to inform treatment, and does so at an advantage over […]
Daxor Corporation to Exhibit at the 22nd Annual Scientific Meeting of the Heart Failure Society of America
NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) at the Gaylord Opryland Hotel and Convention Center in Nashville, TN from […]
Daxor Corporation Announces a 23 Percent Rise in BVA-100 Kit Sales in the Area of Cardiology and Filing of Form N-CSR for June 30, 2018
NEW YORK – August 24, 2018 – Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations filed a Form N-CSR disclosing its schedule of portfolio holdings as of June 30, 2018. In reporting its mid-year results, Daxor Corporation has seen important developments in 2018 including a 23 percent rise […]
Newly Published Data Show Daxor Corporation’s BVA-100 Is Superior To Formula-Based Estimates of Blood Volume In Assessing Patients With Heart Failure
NEW YORK – August 20, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of an investigator-initiated study from Duke University and The Mayo Clinic demonstrating that despite the widespread use of formula-derived estimates of plasma volume in heart failure patients, […]
Daxor Corporation Appoints Kathryn A. Kornafel Vice President of Marketing and Commercial Development
NEW YORK , June 12, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Kathryn A. Kornafel as vice president of Marketing and Commercial Development. “Kathryn’s extensive marketing experience within the diagnostic, cardiovascular and point-of-care arenas position her to […]
Daxor Corporation Initiates Study with Virginia Commonwealth University to Measure Improvement of Survival Rates Following Burn Surgery As A Result of Optimized Blood Volume Assessment
NEW YORK – June 4, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the initiation of an investigator-initiated trial at Virginia Commonwealth University Medical Center that will incorporate the company’s patented BVA-100 diagnostic to assess blood volume loss during burn surgery. “Intravascular […]
A New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in Use
New York, NY, April 19, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the publication of new research utilizing the BVA-100 blood volume analyzer that highlights significant, often unrecognized blood loss in cardiac surgery. The paper entitled “Measurement of Blood Loss in Cardiac Surgery: Still […]
New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session
New York, NY, March 14, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the presentation of new research highlighting the significant benefits to patient outcomes through individualization of care guided by blood volume analysis (BVA). The study by John E. Strobeck, MD, PhD and Wayne […]
Daxor Corporation Announces Positive New Critical Care Research Highlighting Benefit from BVA Use; Daxor Corporation to Exhibit at the American College of Cardiology 2018 Annual Meeting
New York, NY, March 9, 2018 – Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, exhibited at the 2018 Society for Critical Care Medicine Annual Meeting from February 25-28 in San Antonio, Texas where research was presented highlighting the positive clinical benefits of the use of Daxor’s BVA-100 blood […]
Featured
The BVA-100 is the first FDA Cleared machine to accurately measure blood volume in as little as 30 minutes. Review our product literature to learn more.